Salt Lake-based Echelon Research Laboratories Inc. has been awarded a Small Business Innovation Research Phase II grant for research in the delivery of signaling molecules into cancer cells.
The two-year, $940,000 grant is from the National Institute of General Medical Sciences of the National Institutes of Health.
The company is researching methods of delivering signaling molecules through the cell membrane to stimulate changes in cell physiology. The products based on the new Shuttle-PIP technology will be co-marketed with Echelon's corporate partner, Molecular Probes Inc. of Eugene, Ore.
Echelon, located in Research Park adjacent to the University of Utah, is affiliated with the Center for Cell Signaling, a program funded by the state to foster technology development.